Sorin's cardiac resynchronization device wins conditional FDA approval

March 22, 2013 by Sony Salzman

Sorin will begin clinical testing on its SonR cardiac assist device after the FDA grants a conditional investigational device exemption.

Sorin Group

Sorin Group (BIT:SRN) said the FDA granted conditional approval for an investigational device exemption for its SonR cardiac resynchronization device.

The Italian medical device company said it will launch the Respond CRT trial to evaluate the SonR device in more than 1,000 U.S. patients with advanced heart failure.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp